Defines general medical necessity, not medically necessary, and experimental/unproven determinations for laboratory tests and panels for Cigna-administered health benefit plans; applies to providers ordering or performing lab tests under those plans.
Added policy statement for not covered or reimbursable tests and added codes.
>100listed specific CPT/Proprietary codes (partial)
7Medically necessary criteria bullets
3Primary coverage stances
severalTests listed as experimental/investigational
NationalApplicability note
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
Coverage Criteria
Medically Necessary Criteria
A laboratory test or panel of tests is considered medically necessary when ALL of the following are met:
Medically necessary requirements: 1) The testing method for each single test or test in a panel is scientifically valid (analytical validity: accuracy, precision, sensitivity, specificity, reproducibility) based on published, peer-reviewed prospective evidence.
2) Ordered and performed according to the test manufacturer's intended indications for use.
3) Ordered by a qualified health care practitioner practicing within the scope of their license and who is actively managing the individual's care.
4) FDA cleared or approved and/or performed in an appropriately credentialed and certified laboratory setting.
5) Not primarily for the convenience of the individual or health care professional.
6) The type, frequency, extent, site and duration of testing is consistent with the need to obtain laboratory information to assess and/or manage the individual's clinical needs.
7) Each single test or test in a panel is not duplicative or overlapping in clinical intent with other services previously or currently being performed.
Evidence requirement (ANY of the following must be met): 8a) The USPSTF has designated use of the test as a Level A or B recommendation; OR 8b) Published, evidence-based Professional Society/Organization guidance specifically addresses the test's use for the individual's condition; OR 8c) Sufficient published, evidence‑based literature demonstrates the test drives clinical decision-making and improves health outcomes.
Not Medically Necessary
A laboratory test is considered not medically necessary for ANY of the following:
Not medically necessary conditions: 1) Testing intervals or indications performed outside of published USPSTF A & B recommendations and/or published professional society/organization guidelines; 2) Absence of documented changes in the individual's condition requiring further evaluation; 3) Results of the test will not directly impact the clinical management of the individual.
Population screening note: Screening in the general population without specific signs or symptoms or an existing diagnosis that suggests clinical need for the test is Not Medically Necessary unless another Cigna Coverage Policy addresses it.
Experimental/Unproven
The following tests are considered experimental, investigational, or unproven for ANY indication:
Examples of experimental/investigational tests: PreTRM (CPT 0247U); Immunoscore (CPT 0261U); NaviDKD (CPT 0384U); IGoCheck (CPT 0558U); MammoCheck (CPT 0559U); Auria Home Breast Health Assessment (CPT 0458U); PromarkerD (CPT 0385U); NanoDetect-TB (CPT 0574U) — tests lacking sufficient peer‑reviewed evidence to demonstrate safety, effectiveness, or improvement in health outcomes.
Panel composition requirement
Coverage tied to correct panel composition and sampling:
Panel billing and component requirements: The service is correctly coded and eligible for coverage only when the billed panel corresponds exactly to the defined component analytes and the required number of timed/sampled measurements as listed for each panel code.
Examples: 80400 requires Cortisol (82533 x 2); 80412 requires Cortisol (82533 x 6) and ACTH (82024 x 6).
Claims may be denied or adjusted if a billed panel does not include all required component analyte codes and the required timed specimen counts (for example failure to bill cortisol or timed urine volume components for stimulation/suppression panels).
General laboratory medical necessity criteria
Covered when ALL of the following are met
Clinical validity and utility: Test has published, peer-reviewed evidence demonstrating analytical and clinical validity and results will directly impact clinical management of the individual.
Laboratory credentialing and test validation: Test is FDA-approved/cleared and/or performed in a CLIA‑credentialed laboratory appropriate for the complexity of the test; Laboratory Developed Tests (LDTs) must be performed in CLIA high‑complexity laboratories with demonstrated analytic validity.
Panel vs sequential testing: Panel testing is justified when specimen availability or urgency precludes sequential single-test approaches; otherwise sequential testing is preferred.
Repeat testing is performed only when there is documented change in the individual's condition requiring further evaluation or when the minimum retesting interval for the analyte has elapsed based on biochemical properties and clinical context.
Not covered - experimental/investigational tests
Tests classified as experimental, investigational, or unproven are not covered when they meet the following:
Not covered when insufficient evidence: The laboratory test lacks sufficient peer‑reviewed, evidence‑based scientific literature demonstrating safety, effectiveness, or that test results improve health outcomes.
Examples of tests considered not covered/experimental: Includes but is not limited to PreTRM, Immunoscore, NaviDKD, IGoCheck, MammoCheck, Auria Home Breast Health Assessment, PromarkerD, NanoDetect-TB, epigenetic DNA methylation risk‑prediction tests (eg, TruD MDS series), and RenaDx™ — these are listed as experimental/investigational or not covered in the policy.
Epigenetic testing that analyzes DNA methylation patterns to establish risk, likelihood, or susceptibility for developing a disease or condition is not covered or reimbursable. The policy explicitly lists multiple TruD MDS epigenetic risk/susceptibility tests (CPT 0616U–0627U) as examples of this exclusion and states that, more generally, evidence is insufficient to demonstrate that such epigenetic risk‑prediction testing improves health outcomes.
The multi‑gene next‑generation sequencing panel RenaDx™ (CPT 0628U) is specifically identified as not covered or reimbursable in this policy. RenaDx™ is described as a saliva‑based genomic panel of up to 449 genes for kidney disease–related variants, and the policy indicates available evidence is insufficient to demonstrate improved health outcomes.
Coverage for defined laboratory panels is contingent on billing that matches the panel definition. Panels that require specific component analytes and numbers of timed or pooled specimens (for example ACTH/stimulation panels requiring Cortisol (82533 x 2) or CRH panels requiring ACTH (82024 x 6) and Cortisol (82533 x 6)) may be considered incorrectly billed and subject to denial or alternative reimbursement if the required component CPT codes and sample counts are not submitted.
The policy enumerates specific proprietary and CPT/PLA codes that are designated as Not Covered or Reimbursable. Examples called out in the document include codes such as 0616U, 0617U, 0618U, 0619U, 0620U, 0621U, 0622U, 0623U, 0624U, 0625U, 0626U, 0627U, and the multi‑gene panel 0628U. Providers should refer to the code list in the policy when determining coverage.
For many tests listed as excluded or experimental, the policy does not provide explicit clinical indications under which those tests would be covered. The document states that tests lacking sufficient peer‑reviewed evidence to demonstrate safety, effectiveness, or improved health outcomes are classified as experimental/investigational/unproven and therefore excluded from coverage in the absence of stronger evidence.
Screening in the general population without specific signs or symptoms or an existing diagnosis that suggests a clinical need for the test is considered Not Medically Necessary, unless another Cigna Coverage Policy specifically addresses that screening use.
Operationally, this revision added explicit statements and codes for tests designated as not covered or reimbursable. The policy reiterates that determinations depend on the applicable benefit plan and that tests classified as experimental/investigational/unproven — or those without sufficient evidence of clinical utility — may be denied or require prior authorization per plan rules.
The policy lists numerous tests as Experimental, Investigational, or Unproven because published, peer‑reviewed evidence is insufficient to demonstrate analytical and clinical validity or that test results improve patient health outcomes. Examples include proteomic risk tests (e.g., PreTRM® — CPT 0247U), image/AI or algorithmic biomarker panels (e.g., Immunoscore, PromarkerD), predictive diagnostic screening assays (e.g., NaviDKD), and several novel or proprietary assays referenced by CPT/PLA codes.
Laboratory tests determined to be experimental, investigational, or unproven are considered not medically necessary and may be denied or not reimbursed. The policy explains this classification applies when available evidence does not demonstrate safety, effectiveness, or that the test result changes clinical management to improve outcomes.
Coding and Test Codes
Considered Experimental/Investigational/Unproven — Proprietary/PLA (selected examples)CPTExperimental
0247U
PreTRM® (Obstetrics — predictive risk stratification for spontaneous preterm birth; IGFBP4 and SHBG)
0261U
Immunoscore (Oncology — colorectal immune response and recurrence-risk score)
0384U
NaviDKD™ Predictive Diagnostic Screening for Kidney Health (Nephrology — CKD predictive biomarkers)
0385U
Promarker® D (Nephrology — biomarker panel with algorithmic risk score)
Use the most appropriate codes as of the date of service when submitting claims. Claims submitted for services that are not accompanied by covered code(s) under this Coverage Policy will be denied as not covered. Providers should submit the CPT/PLA/Category III or other applicable code(s) that most accurately describe the test performed and include supporting documentation as outlined below.
When billing panels described by CPT/HCPCS, providers must ensure component tests listed in the panel definition are performed and billed appropriately (example: ACTH stimulation panels require cortisol measured on specified number of timed samples; see panel definitions such as 80400–80426).
Incomplete panel component billing (eg, failing to include all required timed or duplicate specimen analytes) may result in claim denial or adjustment.
Unlisted codes (eg, 84999, 86849, 81099, 85999, 86999) or other unlisted procedure codes require submission of additional supporting documentation (test methodology, analytic and clinical validity evidence, specimen requirements, interpretation algorithm) to allow coverage review.
Covered Indications
General
Tests addressing prevention, evaluation, diagnosis, or treatment are covered when they meet the policy's medical necessity criteria (use a more specific policy when available):
General coverage stance: A laboratory test intended to prevent, evaluate, diagnose or treat an illness, injury, disease or its symptoms is considered under this policy; if a test or indication is addressed by another Cigna Coverage Policy, the more specific policy should be used.
Disease-specific indications tied to test descriptions
Disease-specific indications are tied to the test descriptions in the code and notes; explicit medical necessity criteria for each listed test are not provided in these chunks:
Disease-specific indications (implied): Examples include liver disease scoring and NAFLD/NASH risk algorithms, preeclampsia risk assays, transplant rejection risk scores, infectious agent detection assays, oncology prognostic/response assays, hematology/coagulation diagnostics, and blood group genotyping — specific clinical criteria are implied by the test descriptions but explicit coverage rules are in other policy sections.
Frequency Limits & Retesting
Any test — frequency must be consistent with clinical need (type, frequency, extent, site and duration)
Clinical‑need consistencyType, frequency, extent, site and duration of testing must be consistent with the clinical need for the individual
JustificationTesting should be ordered only when results will impact management or diagnosis
Avoid overuseOveruse can lead to harms, unnecessary follow‑up, and inefficient resource use (CADTH/Cited studies)
Panels with multiple timed specimens — timing requirements (no explicit frequency limits)
Timing implicationPanels that require multiple timed specimens (eg, stimulation panels) imply strict timing requirements for specimen collection
Frequency not specifiedThese chunks do not set explicit frequency limits beyond the panel's sample/timing requirements
Ordering Requirements
Note
Order tests only when within practitioner's scope and actively managing care
Ordering clinician must be a qualified health care practitioner practicing within the scope of their license and actively managing the individual's care when ordering tests.
Orders should be part of active patient management and documented in the medical record.
Standard scope-of-practice rules apply.
Note
Request panels that match defined component and specimen requirements
Panel definitions include specific component and timed specimen requirements; ordering clinicians must ensure the requested panel and specimen collection match the panel definition.
Specify the exact stimulation/suppression panel on the order.
Document the timing and number of specimens collected to meet the panel's requirements.
Note
Not Covered Tests
Examples of services identified as not covered in this policy include epigenetic methylation‑based risk/susceptibility testing (multiple TruD MDS CPT codes 0616U–0627U) and the RenaDx™ multi‑gene NGS panel (0628U). Additionally, panel billing that omits required component analyte codes or timed specimen counts (as defined for stimulation/suppression panels) may be considered non‑compliant with the panel definition and thus not covered.
No additional specific not‑covered individual tests are listed in this excerpt beyond the examples detailed elsewhere in the policy; consult the full code lists in the policy for the complete enumeration.
Billing a panel code without submitting the defined component analyte CPT codes and the required number of timed or pooled specimens (for example, failing to bill for the specified cortisol measurements or urine timed‑volume codes for a dexamethasone suppression panel) may be considered inconsistent with the panel definition and could be denied or reimbursed differently.
The document includes many standard and unlisted CPT procedure codes. Some excerpts do not explicitly identify individual tests as not covered; for unlisted codes or services not otherwise specified, additional documentation or adjudication may be required to determine coverage.
No explicit exclusions are presented in this excerpt beyond those already cited; refer to the complete policy for the full list of not‑covered items.
The policy names a series of proprietary and PLA/CPT codes that are designated as Experimental/Investigational and Not Covered. Examples included in the document are CPT/PLA codes 0247U, 0261U, 0384U and a range of newer/novel proprietary codes in the 0616U–0628U series; these are cited as illustrative examples of tests the policy considers not supported by sufficient evidence.
Background
This policy describes general criteria used to determine the clinical usefulness of laboratory tests. Key considerations include analytical validity (accuracy, precision, reproducibility), intended use, qualifications of the ordering clinician, appropriate laboratory credentialing (e.g., CLIA high‑complexity for LDTs), and published evidence that test results will impact clinical management and outcomes.
Analytical validity definitionAccuracy, precision, sensitivity, specificity, and reproducibility of results as demonstrated in published, peer‑reviewed evidence
Role in coverageAnalytical validity is required as part of the medical necessity criteria for laboratory testing
Medically necessary testing definitionA test required to prevent, evaluate, diagnose or treat an illness, injury, disease or its symptoms when it meets all policy criteria including analytical validity, appropriate ordering, laboratory credentialing, non‑duplication, and evidence of clinical usefulness
Ordering requirement
Revision History
2026-05-15focused_reviewLatest
Added policy statement for not covered or reimbursable tests and added codes during focused review.
2026-03-15annual_review
Annual review performed; no clinical policy statement changes noted.
Certain unlisted, novel, or high-complexity tests (including some PLA/Category III codes and LDTs) may require prior authorization per the applicable benefit plan or may be identified in the policy as not covered/experimental and therefore will be denied or not reimbursed.
Laboratory tests must be FDA-cleared/approved for the intended use or performed in a CLIA-certified laboratory with appropriate credentialing. Laboratory-Developed Tests (LDTs) performed under CLIA high-complexity rules remain subject to CLIA requirements and may need additional evidence of analytical and clinical validity for coverage consideration.
Documentation expectations: submit clinical indication, relevant medical record documentation demonstrating medical necessity, test methodology description, evidence of analytic/clinical validity and clinical utility, specimen collection and timed specimen information for panels, and prior authorization when required.
Sequential single-test approaches are preferred when feasible; panel testing is acceptable when specimen availability or urgency precludes sequential testing.
Minimum retesting intervals should be considered; repeat testing without documented change in condition may be denied.
Documentation Required
Panel Definitions and Component Billing Requirements
Panel composition and detailed component documentation are required when billing panel codes. Laboratories and providers are responsible for documenting the exact component analytes performed, the number of timed or pooled samples, and how the panel maps to the billed panel code. Failure to document or bill the required component tests for a panel (for example, ACTH stimulation panels, suppression tests, or multi-sample endocrine stimulation panels) can result in denial or downcoding.
Panel definitions require matching component billing (list component analytes and specimen counts as specified by the panel code).
Detailed panel component documentation must include specimen timing (eg, x2, x3 samples), pooling details if applicable, and individual component CPT codes if billed separately.
If a panel CPT is billed, ensure the laboratory's report and supporting documentation show all required components were performed as defined by the panel code.
For unlisted procedure codes and novel assays, provide supporting materials to permit clinical review. Prior authorization may be required by the plan for certain unlisted or high-complexity tests; when a test is identified in the policy as experimental/investigational/not covered, claims will be denied or not reimbursed per the coverage note.
Unlisted codes (eg, 84999, 86849, 81099) may require submission of test methodology, validation data, intended use, and clinical utility evidence.
Potential prior authorization: unlisted/high-complexity infectious agent detection, immunology procedures, and PLA/Category III tests may require prior authorization depending on the plan.
Prior authorization/coverage note: tests categorized as experimental, investigational, or not covered have had codes added to the policy; such tests may be denied or require prior authorization per plan rules.
Evidence expectations for laboratory testing include published, peer-reviewed prospective data demonstrating analytical validity, clinical validity, and clinical utility that the test results will impact patient management and improve health outcomes. Tests lacking sufficient evidence are considered experimental/investigational and are not covered.
Coding and documentation expectations: submit appropriate CPT code that matches the performed procedure and include clinical rationale and literature support.
Evidence and clinical impact documentation should be provided for algorithmic/interpretive tests and multi-analyte assays (eg, PLA codes) to demonstrate clinical utility.
Tests without sufficient evidence or without documentation of medical necessity may be denied as experimental/investigational.
Note
Other Notes / No Additional Actions Specified
No additional provider actions are explicitly stated in these chunks beyond those summarized above; follow applicable benefit plan document requirements and the Coverage Policy rules for coding, documentation, and prior authorization.
None explicitly stated in these chunks beyond coding, documentation, panel component matching, laboratory credentialing, and prior authorization where applicable.
Endocrine stimulation/suppression testing is indicated for diagnostic evaluation of specific endocrine disorders when panels include the required analytes and timed specimens:
Endocrine stimulation/suppression indications: Evaluation of adrenal insufficiency, congenital adrenal enzyme deficiencies, disorders of the GH/ACTH axis, insulinoma, pheochromocytoma, renin‑aldosterone disorders, and other endocrine stimulation/suppression conditions when the ordered panel matches the defined analytes and required timed specimens for the clinical evaluation.
Each named stimulation/suppression panel must include the specified component tests and sample counts (for example: 80400 must include Cortisol (82533 x 2); 80412 must include Cortisol (82533 x 6) and ACTH (82024 x 6)).
CPT codes and descriptions (no indication rules in these chunks)
CPT code listings and descriptions are provided; these chunks do not include indication‑specific rules:
CPT codes reference only: This section lists CPT codes and brief descriptions for many individual analytes and procedures; explicit indication‑specific coverage rules are not included in these chunks.
Culture, antigen detection, and nucleic acid tests listed
Culture, antigen detection, and nucleic acid tests are listed here; coverage determinations depend on clinical indication and supporting evidence:
Microbiology testing listing: Culture, fungal/mycobacterial, antigen detection, and nucleic acid detection codes (including multiplex panels) are enumerated; specific covered indications are not provided in these chunks and must be determined based on clinical need and evidence supporting clinical utility.
Diagnostic evaluation, management, or prevention when supported by evidence
Diagnostic evaluation, management, or prevention when supported by evidence and when results will directly impact care:
Evidence and impact requirement: Testing is covered when published, peer‑reviewed evidence demonstrates analytical and clinical validity and when results will directly impact clinical management; panels may be allowable when specimen limits or urgency justify panel use.
Laboratory setting requirement: Tests should be FDA‑cleared/approved or performed in CLIA‑certified laboratories appropriate to test complexity.
PreTRM noted as investigational
PreTRM is noted in the policy section listing experimental/investigational tests and no covered indications are provided in this excerpt:
PreTRM status: PreTRM (serum-based proteomic test) is listed among tests considered experimental, investigational, or unproven and no covered clinical indications for asymptomatic screening are provided in these chunks.
DocumentationOrdering clinicians must ensure timing and number of specimens match panel definition
Stimulation/suppression panels — frequency governed by panel sample counts
Governing ruleFrequency and timing for stimulation/suppression panels (eg, CPT 80400‑80439 series) are governed by the panel's specified sample counts and timed specimen protocol
Panel examplesExamples include ACTH, renin, CRH, growth hormone, TRH, dexamethasone suppression and insulin tolerance panels with explicit per‑analyte sample counts
Billing implicationBilled panel must correspond to required component analytes and number of timed measurements to support coverage
Frequency limits (placeholder)
Placeholder frequency limitsNo explicit frequency limits provided in the referenced chunk; CPT lists and descriptions are included
ImplicationProviders should refer to specific panel definitions and general policy frequency guidance when determining repeat testing
ActionConfirm timing/sample requirements for the specific CPT panel being ordered
All relevant laboratory tests — minimum retesting intervals apply
Minimum retesting intervals applyAll relevant laboratory tests are subject to minimum retesting intervals determined by analyte properties and clinical context
Denial considerationRepeat testing may be denied if prior testing exists with no documented change in condition or elapsed minimum interval
Clinical documentationDocument change in clinical status or rationale for earlier retesting to support coverage
General laboratory tests — minimum retesting intervals apply
General labs subject to intervalsGeneral laboratory tests should follow minimum retesting intervals as informed by biochemical properties and CADTH guidance
PurposeIntervals inform clinicians to prevent unnecessary repeat testing and downstream harms
Documentation expectationClinical documentation should justify repeat testing if performed before recommended interval
Ensure orders specify the exact stimulation/suppression panel and sampling protocol
When ordering stimulation/suppression panels, clinicians must request the specific panel and ensure the timing and number of specimens collected align with the panel definition.
Example: For an ACTH stimulation panel, ensure two cortisol samples are obtained and documented (82533 x 2).
For renal vein renin panels, document Renin (84244 x 6) timed samples as required.
Note
No special restrictions on who may order in this excerpt — follow standard rules
No ordering‑clinician restrictions are specified in these policy excerpts; standard clinical practice and payer authorization rules apply.
If payer-specific preauthorization exists, follow that process even if the policy does not restrict ordering clinician type.
Documentation Required
Document clinical rationale and expected impact on management on the order
Ordering clinicians should document the clinical rationale for testing and indicate how results will influence management when placing orders.
Include clinical indication and anticipated management changes in the order and medical record.
Provide supporting literature when tests are newer or high‑complexity.
Note
Follow standard practice and payer authorization rules for who may order tests
The policy does not state specific ordering‑provider restrictions; standard practice and payer authorization rules govern who may order tests.
Confirm any payer-specific authorization or ordering‑provider requirements if applicable.
Note
Tests lacking sufficient peer‑reviewed evidence — for example PreTRM (0247U), Immunoscore (0261U), NaviDKD (0384U), IGoCheck (0558U), MammoCheck (0559U), and other novel assays — are listed among those considered experimental or not covered because current evidence does not demonstrate they improve clinical outcomes.
Must be ordered by a qualified health care practitioner actively managing the individual's care
Impact on careResults must be likely to influence clinical management to meet medical necessity
Anti‑CdtB and anti‑vinculin immunoassay — definition
Test descriptionImmunoassay (eg, ELISA) for Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies using plasma, reported qualitatively as elevated or not elevated
Use case notedReferenced in notes as an immunoassay for specific antibody detection (associated contexts such as post‑infectious IBS are described elsewhere)
Code referenceListed in PLA/CPT code group entries (eg, 0176U) in policy coding sections
ACTH/stimulation panels — definition
Panel definitionACTH/stimulation panels require multiple timed cortisol (and other hormone) measurements as specified by the panel (eg, 2 or more cortisol measurements for ACTH stimulation panels)
ExamplesStandard and variant ACTH/stimulation panels are enumerated with required component analytes and sample counts (see CPT 80400‑80439 series)
Ordering implicationClinicians must order the specific panel and ensure specimen timing/number matches the panel definition
ACTH stimulation panel — detailed definition
ACTH stimulation panel (detailed)Defined panel for adrenal insufficiency must include Cortisol (82533 x 2); variants add analytes (eg, 17‑OHP 83498 x 2; 17‑hydroxypregnenolone 84143 x 2) as specified per CPT codes
CRH panel detailCRH stimulation panel (CPT 80412) requires Cortisol (82533 x 6) and ACTH (82024 x 6)
DocumentationPanel billing must include required component analytes and number of timed/sampled measurements to support coverage
Renin/aldosterone panels — definition
Renin/aldosterone panel compositionRenin (84244) and Aldosterone (82088) with required timed sample counts specified (eg, Aldosterone x2 and Renin x2 for aldosterone suppression evaluation CPT 80408; Renin x6 for renal vein stimulation CPT 80416)
IndicationsUsed for renin stimulation/suppression testing in evaluation of renin‑aldosterone disorders
Billing noteEnsure billed components and sample counts match panel definition to support coverage
Unlisted CPT codes — definition and documentation expectations
Unlisted CPT codes meaningUnlisted procedure codes (eg, 84999, 85999, 86999) denote tests not otherwise specified in CPT and typically require supporting documentation when billed
Documentation expectationProviders should supply supporting clinical and technical documentation for unlisted codes to allow adjudication
Potential prior authorizationUnlisted or highly complex tests may require verification or prior authorization per payer rules
Multiplex amplified probe technique — definition
Multiplex amplified probe techniqueA nucleic acid detection method that can detect multiple pathogen targets in a single assay (eg, CNS pathogen panels 87483, GI panels 87505) using multiplex amplified probe techniques
ApplicationEnables detection of 3–25 targets depending on panel (examples cited in CPT descriptors)
Coding implicationMultiplex panels may have specific CPT codes and may require documentation of targets tested
Experimental/Investigational definitionTests lacking sufficient peer‑reviewed, evidence‑based literature to demonstrate safety, effectiveness, or that results improve health outcomes are considered experimental/investigational/unproven
Coverage consequenceSuch tests are listed as not covered or not reimbursable when they meet this evidence threshold
LDT noteLDTs without sufficient evidence are also subject to this classification despite CLIA analytic validation
Laboratory Developed Test (LDT) — definition
LDT definitionLaboratory Developed Test (LDT) — an in‑vitro diagnostic test designed, manufactured, and used within a single CLIA‑certified laboratory for high‑complexity testing
Regulatory contextLDTs are subject to CLIA analytic validity requirements but are not FDA‑regulated in the same way as cleared/approved IVDs
Coverage implicationLDTs must demonstrate analytic validity and clinical utility to meet medical necessity and coverage requirements
Experimental/investigational test — definition (duplicate)
Experimental/investigational test definitionDuplicate: laboratory tests lacking sufficient peer‑reviewed evidence to demonstrate safety, effectiveness, or improved outcomes
Use in policyApplied to named tests in the policy when evidence is insufficient
AdjudicationClaims for such tests may be denied or not reimbursed per policy
Laboratory Developed Test (LDT) — definition (duplicate)
LDT definition (duplicate)An in vitro diagnostic test designed, manufactured, and used within a single CLIA‑certified laboratory, subject to CLIA analytic validity requirements
Regulatory noteLDTs are not FDA cleared but must meet CLIA high‑complexity lab standards per policy
Coverage noteLDTs require evidence of analytic validity and clinical utility for coverage
Policy updated and codes added during focused review.
2025-11-15focused_review
Policy updated and codes added during focused review.